Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 20, Issue 4, 2014, Pages 452-455

  Kobylecki, Christopher ^a,b   Burn, David J ^c   Kass Iliyya, Lewis ^a,b   Kellett, Mark W ^b   Crossman, Alan R ^d   Silverdale, Monty A ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Clinical trial; Levodopa induced dyskinesia; Parkinson's disease; Topiramate

Indexed keywords

AMANTADINE; LEVODOPA; PLACEBO; TOPIRAMATE; ANTICONVULSIVE AGENT; ANTIPARKINSON AGENT; FRUCTOSE;

ADULT; AGED; ANXIETY; ARTICLE; BREATHING DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSKINESIA; FEMALE; GERIATRIC DEPRESSION SCALE; HALLUCINATION; HUMAN; LANG FAHN ACTIVITIES OF DAILY LIFE DYSKINESIA SCALE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; UNIFIED PARKINSON DISEASE RATING SCALE; XEROSTOMIA; ANALOGS AND DERIVATIVES; DYSKINESIA, DRUG-INDUCED; MIDDLE AGED;

ADULT; AGED; ANTICONVULSANTS; ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; FRUCTOSE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84897956912     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.01.016     Document Type: Article

References (12)

1. Crosby N.J., Deane K.H., Clarke C.E. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003, CD003467.
2. Calon F., Rajput A.H., Hornykiewicz O., Bedard P.J., Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 2003, 14:404-416.
3. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000, 54:1589-1595.
4. Kobylecki C., Cenci M.A., Crossman A.R., Ravenscroft P. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. JNeurochem 2010, 114:499-511.
5. Silverdale M.A., Nicholson S.L., Crossman A.R., Brotchie J.M. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord 2005, 20:403-409.
6. Kobylecki C., Hill M.P., Crossman A.R., Ravenscroft P. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Mov Disord 2011, 26:2354-2363.
7. Fox S., Silverdale M., Kellett M., Davies R., Steiger M., Fletcher N., et al. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov Disord 2004, 19:554-560.
8. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol 2001, 58:1660-1668. Parkinson Study Group.
9. Fox S.H., Lang A.E., Brotchie J.M. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Mov Disord 2006, 21:1578-1594.
10. Shank R.P., Maryanoff B.E. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther 2008, 14:120-142.
11. Angehagen M., Ronnback L., Hansson E., Ben-Menachem E. Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. JNeurochem 2005, 94:1124-1130.
12. Lees A., Fahn S., Eggert K.M., Jankovic J., Lang A., Micheli F., et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord 2012, 27:284-288.